Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Increase of waking and reduction of NREM and REM sleep after nitric oxide synthase inhibition: prevention with GABA(A) or adenosine A(1) receptor agonists
Autore:
Monti, JM; Jantos, H; Monti, D;
Indirizzi:
Clin Hosp, Dept Therapeut & Pharmacol, Montevideo 11300, Uruguay Clin Hosp Montevideo Uruguay 11300 Pharmacol, Montevideo 11300, Uruguay Univ Pittsburgh, Sch Med, Western Psychiat Inst & Clin, Pittsburgh, PA USAUniv Pittsburgh Pittsburgh PA USA ychiat Inst & Clin, Pittsburgh, PA USA
Titolo Testata:
BEHAVIOURAL BRAIN RESEARCH
fascicolo: 1, volume: 123, anno: 2001,
pagine: 23 - 35
SICI:
0166-4328(20010827)123:1<23:IOWARO>2.0.ZU;2-9
Fonte:
ISI
Lingua:
ENG
Soggetto:
EYE-MOVEMENT SLEEP; RAT HIPPOCAMPAL SLICES; DORSAL RAPHE NUCLEUS; FREELY MOVING CAT; EFFLUX IN-VIVO; BASAL FOREBRAIN; ACETYLCHOLINE-RELEASE; STRIATAL DOPAMINE; BEHAVIORAL STATE; GABAERGIC INNERVATION;
Keywords:
nitric oxide; nitric oxide synthase; L-NAME; muscimol; L-PIA; waking; REM sleep; dorsal raphe nuclei;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
71
Recensione:
Indirizzi per estratti:
Indirizzo: Monti, JM Clin Hosp, Dept Therapeut & Pharmacol, 2833-602 Zudanez St, Montevideo 11300, Uruguay Clin Hosp 2833-602 Zudanez St Montevideo Uruguay 11300 Uruguay
Citazione:
J.M. Monti et al., "Increase of waking and reduction of NREM and REM sleep after nitric oxide synthase inhibition: prevention with GABA(A) or adenosine A(1) receptor agonists", BEH BRA RES, 123(1), 2001, pp. 23-35

Abstract

The effect of NC-nitro-L-arginine methyl ester (L-NAME), a competitive inhibitor of enzyme nitric oxide synthase (NOS), on spontaneous sleep during the light period, was studied in adult rats implanted for chronic sleep recordings. L-NAME was injected by subcutaneous (s.c.) route or was infused directly into the dorsal raphe nucleus (DRN). Subcutaneous (46.0-185.0 mu mol/kg) administration of L-NAME increased waking (W), slow wave sleep (SWS) and rapid-eye-movement sleep (REMS) latency, whereas SWS, REMS and the numberof REM periods were reduced. Direct application of L-NAME into the DRN (0.37-1.1 mu mol) induced an increment of W and a reduction of SWS and REMS. Values corresponding to SWS and REMS latency, and the number of REM periods remained within control levels. Subcutaneous administration of the GABA, receptor agonist muscimol (1.7-3.5 mu mol/kg) or the adenosine A, receptor agonist L-PIA [L(-)N-6-(2-phenylisopropyl)adenosine] (0.1-0.3 mu mol/kg) induced slight but inconsistent changes of W, light sleep (LS), SWS and REMS that did not attain significance. Pretreatment with muscimol (1.7-3.5 mu mol/kg, s.c.) or L-PIA (0.1-0.3 mu mol/kg, s.c.) antagonized the increase of W and reduction of SWS and REMS induced by s.c. (92.0 mu mol/kg) or intra-DRN(0.74 mu mol) administration of L-NAME. However, neither muscimol nor L-PIA prevented the increase of REMS latency induced by L-NAME 92.0 mu mol/kg, s.c. Our findings tend to indicate that the change of behavioral state observed after systemic or intra-DRN administration of L-NAME is partly relatedto the reduction of GABA and adenosine at critical sites in the CNS. (C) 2001 Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 20:58:03